President Trump Orders RFK Jr to "Streamline" Pharmaceutical Expansion

You can read the entire Executive Order 14293 here, titled “Regulatory Relief To Promote Domestic Production of Critical Medicines,” dated May 5, 2025.

Some excerpts.

In Section 1, Trump bragged about an Executive Order of his previous administration, #13944 of August 6, 2020, which accelerated the development of deadly “countermeasures” to a fictional virus. The “countermeasures” killed untold large numbers of American citizens; the fictional virus killed none.

Purpose. During my first term, my Administration took unprecedented action to improve the well-being of the American people by restoring capacity for domestic production of critical pharmaceutical products. Notably, in Executive Order 13944 of August 6, 2020 (Combating Public Health Emergencies and Strengthening National Security By Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made In The United States), I directed each executive department and agency involved in the procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs to take a variety of actions to increase their domestic procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs, as defined in section 7 of that order, and to identify vulnerabilities in our Nation's supply chains for these products. Unfortunately, the prior administration did too little to advance these goals.

Death totals and pharmaceutical profits soared after Executive Order 13944 in 2020, but it’s not enough for the Pharmaceutical Industry or Donald Trump in his second Administration. The Pharmaceutical Industry want to use their profits to expand production of deadly products, but existing regulations are slowing their expansion. They say their deadly products are required for “national security,” a term that has become misused and abused by the Federal Government to destroy the National Security of the United States.

Section 3:

One key area of concern is the length of time it takes to build pharmaceutical manufacturing facilities in the United States today. New construction must navigate myriad Federal, State, and local requirements ranging from building standards and zoning restrictions to environmental protocols that together diminish the certainty needed to generate investment for large manufacturing projects. For pharmaceutical manufacturing, these barriers are heightened by unannounced inspections of domestic manufacturers by the Food and Drug Administration (FDA), which are more frequent than such inspections at international facilities. Industry estimates suggest that building new manufacturing capacity for pharmaceuticals and critical inputs may take as long as 5 to 10 years, which is unacceptable from a national security standpoint.

Trump directed his co-associate of child rapist and human trafficker Jeffrey Epstein, Robert Kennedy Jr, Secretary of Health and Human Services, to find ways to “streamline” the regulatory process to speed up the approval process for pharmaceutical facilities that will crank out more deadly countermeasures for the next Plandemics.

Streamlining Review of Domestic Pharmaceutical Manufacturing by the Food and Drug Administration. Within 180 days of the date of this order, the Secretary of Health and Human Services, through the Commissioner of Food and Drugs (FDA Commissioner), shall review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and shall take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing. The FDA Commissioner's review shall encompass all regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity, emerging technologies that enable the manufacturing of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States. The FDA Commissioner shall:

etc.

Charles Wright